MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.54
-0.03 (-0.54%)
At close: Feb 24, 2026, 4:00 PM EST
5.61
+0.07 (1.26%)
After-hours: Feb 24, 2026, 7:55 PM EST
MannKind Employees
As of December 31, 2024, MannKind had 407 total employees, including 403 full-time and 4 part-time employees. The number of employees decreased by 7 or -1.69% compared to the previous year.
Employees
407
Change (1Y)
-7
Growth (1Y)
-1.69%
Revenue / Employee
$770,975
Profits / Employee
$71,826
Market Cap
1.70B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 407 | -7 | -1.69% | 403 | 4 |
| Dec 31, 2023 | 414 | 19 | 4.81% | 411 | 3 |
| Dec 31, 2022 | 395 | 46 | 13.18% | 391 | 4 |
| Dec 31, 2021 | 349 | 108 | 44.81% | 348 | 1 |
| Dec 31, 2020 | 241 | 8 | 3.43% | 240 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Syndax Pharmaceuticals | 270 |
| Zymeworks | 263 |
| Tango Therapeutics | 155 |
| Innoviva | 127 |
| Kodiak Sciences | 123 |
| Definium Therapeutics | 74 |
| Tyra Biosciences | 60 |
| RAPT Therapeutics | 60 |
MNKD News
- 5 days ago - MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 days ago - MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 15 days ago - MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) - GlobeNewsWire
- 18 days ago - 2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion - Seeking Alpha
- 4 weeks ago - MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - GlobeNewsWire
- 5 weeks ago - MoneyShow's Best Investment Ideas For 2026: Part 5 - Seeking Alpha
- 6 weeks ago - 6 stocks and ETFs that these unsung market heroes see outperforming in 2026 - Market Watch
- 6 weeks ago - MannKind Provides Business Updates and 2026 Growth Drivers - GlobeNewsWire